300871 Stock Overview
Engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
Hvsen Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.95 |
| 52 Week High | CN¥16.49 |
| 52 Week Low | CN¥7.61 |
| Beta | 0.36 |
| 11 Month Change | -11.96% |
| 3 Month Change | -23.85% |
| 1 Year Change | -50.56% |
| 33 Year Change | -76.20% |
| 5 Year Change | n/a |
| Change since IPO | -80.72% |
Recent News & Updates
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21
Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Recent updates
Hvsen Biotechnology Co., Ltd. (SZSE:300871) Shares Could Be 21% Below Their Intrinsic Value Estimate
Aug 21Take Care Before Jumping Onto Hvsen Biotechnology Co., Ltd. (SZSE:300871) Even Though It's 27% Cheaper
Jun 05Hvsen Biotechnology Co., Ltd. (SZSE:300871) Stocks Shoot Up 37% But Its P/E Still Looks Reasonable
Mar 29Shareholder Returns
| 300871 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.7% | -2.7% | -1.3% |
| 1Y | -50.6% | -18.4% | -21.4% |
Return vs Industry: 300871 underperformed the CN Pharmaceuticals industry which returned -17.4% over the past year.
Return vs Market: 300871 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
| 300871 volatility | |
|---|---|
| 300871 Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.6% |
| 10% least volatile stocks in CN Market | 3.6% |
Stable Share Price: 300871's share price has been volatile over the past 3 months.
Volatility Over Time: 300871's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 1,068 | Weiyuan Zhang | www.whhsyy.com |
Hvsen Biotechnology Co., Ltd. engages in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. Its products include tylvalosin tartrate powders and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products. The company produces various veterinary drug products of raw materials and preparations, as well as traditional Chinese medicines extractives.
Hvsen Biotechnology Co., Ltd. Fundamentals Summary
| 300871 fundamental statistics | |
|---|---|
| Market cap | CN¥1.30b |
| Earnings (TTM) | -CN¥51.00m |
| Revenue (TTM) | CN¥1.01b |
1.3x
P/S Ratio-25.5x
P/E RatioIs 300871 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300871 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.01b |
| Cost of Revenue | CN¥816.07m |
| Gross Profit | CN¥190.91m |
| Other Expenses | CN¥241.91m |
| Earnings | -CN¥51.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 18.96% |
| Net Profit Margin | -5.06% |
| Debt/Equity Ratio | 70.6% |
How did 300871 perform over the long term?
See historical performance and comparison